Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31071013 | 0.89 | GAA (0.35) | GAACYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL1691829 | 0.85 | GAA (0.42) | GAACYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL13790227 | 0.85 | GAA (0.42) | GAACYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL14105290 | 0.83 | ALDH1A1 (0.44) | GAACYP3A4ALDH1A1TSHRMAPT | |
| SCHEMBL4421264 | 0.83 | ALDH1A1 (0.43) | GAACYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL15438417 | 0.81 | ACHE (0.36) | GAACYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL16978357 | 0.81 | TDP1 (0.38) | GAACYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL1443822 | 0.81 | HTT (0.37) | GAACYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL11197693 | 0.81 | CTSA (0.39) | GAACYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL7009353 | 0.81 | CYP2D6 (0.39) | GAACYP3A4CYP2C9CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1543 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718797-B2 | Eight diasteromers of vittatalactone and methods of making, and methods of attracting acalymma vittatum | The United States of America, as represented by the Secretary of Agirculture (US) | 2017-08-01 | — | — | US | claimed |
| US-20160052901-A1 | Eight Diasteromers of Vittatalactone and Methods of Making, and Methods of Attracting Acalymma vittatum | CHEMVEDA LIFE SCIENCES, INC. | 2016-02-25 | — | — | US | claimed |
| CN-102105509-B | Aliphatic polyester resin and production method thereof | TOYO BOSEKI | 2014-04-23 | — | — | CN | claimed |
| US-8574757-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-11-05 | — | — | US | claimed |
| US-20120264011-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-10-18 | — | — | US | claimed |
| EP-1038900-B1 | Double metal cyanide catalysts for the production of polyetherpolyols | BAYER MATERIALSCIENCE AG (DE) | 2004-07-14 | — | — | EP | claimed |
| US-6468939-B1 | ESTERS OF PHOSPHORIC ACID, PHOSPHOROUS ACID, PHOSPHONIC ACID, PHOSPHONOUS ACID, PHOSPHINIC ACID OR PHOSPHINOUS ACID; COMPLEXING LIGANDS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-22 | — | — | US | claimed |
| EP-1001951-B1 | THIAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE | SCHERING AG (DE) | 2002-09-25 | — | — | EP | claimed |
| US-6384230-B1 | 2,6-DIMETHYL-5-((4-ETHOXYPHENYL)-METHOXY)-7-(2-METHYLTHIAZOL-4-YL)HEPTA -2,6-DIENOIC ACID ETHYL ESTER FROM MALIC ACID, WITTIG REACTION WITH 2-METHYL-4-THIAZOLYLMETHYL TRIPHENYL PHOSPHONIUM BROMIDE; INTERMEDIATES FOR EPOTHILONE A OR B | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-05-07 | — | — | US | claimed |
| EP-1017687-A4 | PROCESS OF MAKING 3-ARYLOXY, 4-ARYL FURAN-2-ONES USEFUL AS INHIBITORS OF COX-2 | MERCK & CO INC (US) | 2001-10-31 | — | — | EP | claimed |
| EP-1038900-A2 | Double metal cyanide catalysts for the production of polyetherpolyols | Bayer Aktiengesellschaft (DE) | 2000-09-27 | — | — | EP | claimed |
| EP-1017687-A1 | PROCESS OF MAKING 3-ARYLOXY, 4-ARYL FURAN-2-ONES USEFUL AS INHIBITORS OF COX-2 | Merck & Co., Inc. (US) | 2000-07-12 | — | — | EP | claimed |
| WO-1999015513-A1 | PROCESS OF MAKING 3-ARYLOXY, 4-ARYL FURAN-2-ONES USEFUL AS INHIBITORS OF COX-2 | MERCK & CO., INC. (US) | 1999-04-01 | — | — | WO | claimed |
| US-5386063-A | Forming a synthetic carotenoids chemical intermediates by reacting triethyl-2-phosphonopropionate with fumarylaldehyde and/or fumarylaldehyde dimethylacetal containing carbon isotope | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1995-01-31 | — | — | US | claimed |
| EP-0260305-B1 | QUINOLINYL ETHER TETRAZOLE AS AGENT FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-12-16 | — | — | EP | claimed |
| US-12637430-B2 | Interleukin-17 (IL-17) inhibitors | HITGEN INC. (CN) | 2026-05-26 | — | — | US | disclosed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-4151172-A | Phosphonoacyl prolines and related compounds | E. R. SQUIBB & SONS, INC. (US) | 1979-04-24 | — | — | US | disclosed |
| EP-0000833-A1 | Derivatives of phosphonoacyl prolines and their pharmaceutical use | E.R. Squibb & Sons, Inc. (US) | 1979-02-21 | — | — | EP | disclosed |
| US-4136197-A | HYPOGLYCAEMICALLY AND HYPOLIPIDAEMICALLY EFFECTIVE N-SUBSTITUTED CARBOXYLIC ACID AMIDES | BOEHRINGER MANNHEIM GMBH (DE) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637430-B2 | Interleukin-17 (IL-17) inhibitors | IL17A, IL2, IL23R | GAA 4577/4885CYP3A4 203/4885CYP2C9 259/4885 |
| US-20160052901-A1 | Eight Diasteromers of Vittatalactone and Methods of Making, and Methods of Attracting Acalymma vittatum | DAGLA, NOTUM, DAGLB | GAA 587/4885CYP3A4 1784/4885CYP2C9 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.